Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Swiss Group for Clinical Cancer Research

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 1965-01-01

Employees: -

Market Cap: -

Website: http://www.sakk.ch/

Clinical Trials

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Phase 2

Completed

Conditions: Malignant Pleural Mesothelioma
Non-small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Atezolizumab

First Posted Date: 2020-07-21

Last Posted Date: 2024-07-01

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 68

Registration Number: NCT04480372

Locations: 🇨🇭
HFR Fribourg, Fribourg, Villars-sur-Glâne, Switzerland
🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland

and more 9 locations

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Phase 2

Active, not recruiting

Conditions: Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Durvalumab
Drug: carboplatin
Drug: etoposide
Radiation: Thoracic radiotherapy

First Posted Date: 2020-07-16

Last Posted Date: 2023-09-13

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 46

Registration Number: NCT04472949

Locations: 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭
Universitaetsspital Basel, Basel, Switzerland
🇨🇭
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland

and more 11 locations

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer
NSCLC

Interventions: Drug: Durvalumab
Radiation: Radiotherapy

First Posted Date: 2020-01-29

Last Posted Date: 2025-03-13

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 90

Registration Number: NCT04245514

Locations: 🇩🇪
Universitätsklinikum Tübingen, Tübingen, Germany
🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland

and more 10 locations

Prostate Cancer Biobank

Active, not recruiting

Conditions: Prostatic Neoplasms

First Posted Date: 2019-07-18

Last Posted Date: 2022-06-08

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 1323

Registration Number: NCT04024475

Locations: 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Inselspital Bern, Bern, Switzerland

and more 9 locations

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: IP-001
Device: Thermal Ablation

First Posted Date: 2019-06-21

Last Posted Date: 2025-03-18

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 28

Registration Number: NCT03993678

Locations: 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Kantonsspital Graubünden, Chur, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Phase 2

Active, not recruiting

Conditions: Testicular Cancer
Seminoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2019-05-06

Last Posted Date: 2025-01-16

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 135

Registration Number: NCT03937843

Locations: 🇩🇪
Vivantes Klinikum Am Urban, Berlin, Germany
🇩🇪
Helios Klinikum Berlin-Buch, Berlin, Germany
🇩🇪
Evang. Kliniken Essen-Mitte, Essen, Germany

and more 16 locations

Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

First Posted Date: 2019-04-19

Last Posted Date: 2023-03-09

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 57

Registration Number: NCT03921996

Locations: 🇨🇭
Kantonsspital Aarau AG, Aarau, Switzerland
🇨🇭
Universitätsspital Basel, Basel, Switzerland
🇨🇭
Inselspital, Bern, Bern, Switzerland

and more 8 locations

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Other: Mono-chemotherapy
Other: Endocrine-Therapy

First Posted Date: 2019-04-05

Last Posted Date: 2021-06-16

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 25

Registration Number: NCT03905343

Locations: 🇦🇹
Med. Univ. Klinik Graz, Graz, Austria
🇦🇹
Tirol Kliniken - BrustGesundheitZentrum Tirol, Innsbruck, Austria
🇦🇹
Salzburger Landeskliniken - Universitätsklinikum Salzburg, Salzburg, Austria

and more 31 locations

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Phase 1

Terminated

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Copanlisib
Drug: Venetoclax

First Posted Date: 2019-03-22

Last Posted Date: 2022-04-01

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 7

Registration Number: NCT03886649

Locations: 🇨🇭
Universitaetsspital Basel, Basel, Switzerland
🇨🇭
Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
🇨🇭
Inselspital, Bern, Switzerland

and more 3 locations

Activity Program During Aromatase Inhibitor Therapy

Not Applicable

Completed

Conditions: Early Breast Cancer

First Posted Date: 2018-12-24

Last Posted Date: 2023-06-27

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 375

Registration Number: NCT03786198

Locations: 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
CABA - Zentrum für Onkologie, Psychologie und Bewegung, Basel, Switzerland

and more 29 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy